JPH10513433A - 殺菌性、浸透性が向上したタンパク質及び界面活性剤を含有する医薬組成物 - Google Patents
殺菌性、浸透性が向上したタンパク質及び界面活性剤を含有する医薬組成物Info
- Publication number
- JPH10513433A JPH10513433A JP6518213A JP51821394A JPH10513433A JP H10513433 A JPH10513433 A JP H10513433A JP 6518213 A JP6518213 A JP 6518213A JP 51821394 A JP51821394 A JP 51821394A JP H10513433 A JPH10513433 A JP H10513433A
- Authority
- JP
- Japan
- Prior art keywords
- surfactant
- poloxamer
- bpi
- polysorbate
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.ポリソルベート界面活性剤及びポロキサマー界面活性剤を配合して、BPI タンパク質またはその生物学的に活性を有する断片、類似体もしくは変異体を含 む医薬組成物。 2.前記ポロキサマー界面活性剤が、約14よりも大であるHLB値、及び室温に て、0.1%の濃度で測定した場合に10〜70mN/m の間の表面張力を有することによ りその特徴が表される、請求項1に記載の医薬組成物。 3.前記ポロキサマー界面活性剤がポロキサマー188である、請求項1に記載 の医薬組成物。 4.前記ポリソルベート界面活性剤が、約10よりも大であるHLB値、及び室温 にて、0.1%の濃度で測定した場合に10〜70mN/m の間の表面張力を有することに よりその特徴が表される、請求項1に記載の医薬組成物。 5.前記ポリソルベート界面活性剤がポリソルベート80である、請求項1に記 載の医薬組成物。 6.前記ポロキサマー界面活性剤が、約0.01重量%〜約1重量%の濃度で存在 する、請求項1に記載の医薬組成物。 7.前記ポリソルベート界面活性剤が、約0.0005重量%〜約1重量%の濃度で 存在する、請求項1に記載の医薬組成物。 8.ポリソルベート界面活性剤及びポロキサマー界面活性剤を配合して、BPI タンパク質の生物学的に活性を有するアミノ末端断片またはその類似体もしくは 変異体を含む医薬組成物。 9.ポロキサマー界面活性剤を配合して、BPIタンパク質またはその生物学的 に活性を有する断片、類似体もしくは変異体を含む医薬組成物。 10.前記ポロキサマー界面活性剤が、約14よりも大であるHLB値、及び室温に て、0.1%の濃度で測定した場合に10〜70mN/m の間の表面張力を有することによ りその特徴が表される、請求項9に記載の医薬組成物。 11.前記ポロキサマー界面活性剤がポロキサマー188である、請求項9に記載 の医薬組成物。 12.ポロキサマー界面活性剤を配合して、BPIタンパク質の生物学的に活性を 有するアミノ末端断片またはその類似体もしくは変異体を含む医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1236093A | 1993-02-02 | 1993-02-02 | |
US08/012,360 | 1993-02-02 | ||
PCT/US1994/001239 WO1994017819A1 (en) | 1993-02-02 | 1994-02-02 | Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005052149A Division JP2005145986A (ja) | 1993-02-02 | 2005-02-25 | 殺菌性/浸透性増大タンパク質(Bactericidal/PermeabilityIncreasingprotein:BPI)及び界面活性剤を含有する医薬組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10513433A true JPH10513433A (ja) | 1998-12-22 |
JP3946246B2 JP3946246B2 (ja) | 2007-07-18 |
Family
ID=21754603
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51821394A Expired - Fee Related JP3946246B2 (ja) | 1993-02-02 | 1994-02-02 | 殺菌性/浸透性増大タンパク質(Bactericidal/Permeability Increasing protein:BPI)及び界面活性剤を含有する医薬組成物 |
JP2005052149A Withdrawn JP2005145986A (ja) | 1993-02-02 | 2005-02-25 | 殺菌性/浸透性増大タンパク質(Bactericidal/PermeabilityIncreasingprotein:BPI)及び界面活性剤を含有する医薬組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005052149A Withdrawn JP2005145986A (ja) | 1993-02-02 | 2005-02-25 | 殺菌性/浸透性増大タンパク質(Bactericidal/PermeabilityIncreasingprotein:BPI)及び界面活性剤を含有する医薬組成物 |
Country Status (13)
Country | Link |
---|---|
US (5) | US5488034A (ja) |
EP (1) | EP0682524B1 (ja) |
JP (2) | JP3946246B2 (ja) |
CN (1) | CN1163264C (ja) |
AT (1) | ATE206308T1 (ja) |
AU (1) | AU695125B2 (ja) |
CA (1) | CA2155005C (ja) |
DE (1) | DE69428521T2 (ja) |
DK (1) | DK0682524T3 (ja) |
ES (1) | ES2164098T3 (ja) |
HK (1) | HK1014156A1 (ja) |
PT (1) | PT682524E (ja) |
WO (1) | WO1994017819A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006502116A (ja) * | 2002-07-12 | 2006-01-19 | メダレックス, インク. | タンパク質の酸化分解を防ぐ方法及び組成物 |
WO2009034958A1 (ja) * | 2007-09-12 | 2009-03-19 | Jsr Corporation | タンパク安定化剤およびその製造方法、タンパク安定化剤の使用方法、ならびにタンパク安定化方法 |
WO2022202947A1 (ja) * | 2021-03-24 | 2022-09-29 | Jcrファーマ株式会社 | 安定な水性医薬組成物又は凍結乾燥医薬組成物 |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6277410B1 (en) | 1992-10-08 | 2001-08-21 | Supratek Pharma Inc. | Copolymer compositions for oral delivery |
US6093391A (en) * | 1992-10-08 | 2000-07-25 | Supratek Pharma, Inc. | Peptide copolymer compositions |
US6153193A (en) * | 1993-04-28 | 2000-11-28 | Supratek Pharma Inc. | Compositions for targeting biological agents |
AU695125B2 (en) * | 1993-02-02 | 1998-08-06 | Xoma Corporation | Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant |
US5420019A (en) * | 1993-02-02 | 1995-05-30 | Xoma Corporation | Stable bactericidal/permeability-increasing protein muteins |
US5858974A (en) * | 1995-07-20 | 1999-01-12 | Xoma Corporation | Anti-fungal peptides |
US5652332A (en) * | 1993-03-12 | 1997-07-29 | Xoma | Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof |
US6214789B1 (en) | 1993-03-12 | 2001-04-10 | Xoma Corporation | Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products |
AU7175694A (en) * | 1993-06-17 | 1995-01-17 | Xoma Corporation | Lipopolysaccharide binding protein derivatives |
US5770561A (en) * | 1993-07-14 | 1998-06-23 | Xoma Corporation | Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products |
AU7330994A (en) * | 1993-07-14 | 1995-02-13 | Xoma Corporation | Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products |
US6759203B1 (en) | 1993-09-22 | 2004-07-06 | Xoma Corporation | Method for quantifying BPI in body fluids |
CN1133634A (zh) * | 1993-09-22 | 1996-10-16 | 爱克斯欧玛公司 | 定量体液中的bpi的方法 |
WO1995008344A1 (en) * | 1993-09-22 | 1995-03-30 | Xoma Corporation | Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein product and antibiotic |
AU703192B2 (en) * | 1994-01-14 | 1999-03-18 | Xoma Corporation | Anti-gram-positive bacterial methods and materials |
CA2181165C (en) * | 1994-01-14 | 2007-06-05 | Roger G. Ii Little | Anti-fungal methods and materials |
US5447913A (en) * | 1994-03-11 | 1995-09-05 | Xoma Corporation | Therapeutic uses of bactericidal/permeability-increasing protein dimer products |
US5830860A (en) * | 1994-03-24 | 1998-11-03 | Regents Of The University Of Minnesota | Peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use |
US5786324A (en) * | 1994-03-24 | 1998-07-28 | Regents Of The University Of Minnesota | Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use |
US5932544A (en) * | 1994-05-31 | 1999-08-03 | Xoma Corporation | Bactericidal/permeability-increasing protein (BPI) compositions |
US6271203B1 (en) | 1994-07-07 | 2001-08-07 | Xoma Corporation | Anti-protozoan methods and materials |
US5646114A (en) * | 1994-07-11 | 1997-07-08 | Xoma Corporation | Anti-protozoan methods |
US6221959B1 (en) | 1994-11-18 | 2001-04-24 | Supratek Pharma, Inc. | Polynucleotide compositions |
US6353055B1 (en) | 1994-11-18 | 2002-03-05 | Supratek Pharma Inc. | Polynucleotide compositions |
US5912228A (en) * | 1995-01-13 | 1999-06-15 | Xoma Corporation | Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products |
US5494896A (en) * | 1995-03-31 | 1996-02-27 | Xoma Corporation | Method of treating conditions associated with burn injuries |
EP0861088A1 (en) * | 1995-11-14 | 1998-09-02 | Xoma Corporation | Bactericidal permeability increasing protein (bpi) for treating conditions associated with corneal injury |
US5686414A (en) * | 1995-11-14 | 1997-11-11 | Xoma Corporation | Methods of treating conditions associated with corneal transplantation |
US5741779A (en) | 1996-05-10 | 1998-04-21 | Xoma Corporation | Antithrombotic materials and methods |
CA2253837C (en) | 1996-05-10 | 2002-07-02 | Xoma Corporation | Therapeutic uses of bpi protein products for human meningococcemia |
CA2255539C (en) * | 1996-05-23 | 2005-09-27 | Xoma Corporation | Therapeutic uses of bpi protein products in humans with hemorrhage due to trauma |
CA2255865C (en) | 1996-05-24 | 2008-10-14 | The Regents Of The University Of Minnesota | Synthesis of soluble beta-sheet forming peptides |
US5888973A (en) * | 1996-08-09 | 1999-03-30 | Xoma Corporation | Anti-chlamydial uses of BPI protein products |
AU6358898A (en) * | 1996-09-09 | 1998-04-17 | Alexander V Kabanov | Fluorinated copolymeric pharmaceutical adjuncts |
WO1998019694A1 (en) * | 1996-11-01 | 1998-05-14 | Xoma Corporation | Therapeutic uses of bpi protein products in cystic fibrosis patients |
US6482796B2 (en) * | 1996-11-01 | 2002-11-19 | Xoma Corporation | Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients |
US20030190307A1 (en) * | 1996-12-24 | 2003-10-09 | Biogen, Inc. | Stable liquid interferon formulations |
US6093573A (en) * | 1997-06-20 | 2000-07-25 | Xoma | Three-dimensional structure of bactericidal/permeability-increasing protein (BPI) |
FR2764800B1 (fr) * | 1997-06-23 | 1999-09-10 | Sanofi Sa | Composition pharmaceutique solide contenant des derives de benzofuranne |
US5990082A (en) | 1997-10-22 | 1999-11-23 | Xoma Corporation | Uses of lipopolysaccharide binding protein |
US6013631A (en) * | 1998-06-19 | 2000-01-11 | Xoma Corporation | Bactericidal/permeability-increasing protein (BPI) deletion analogs |
US20030166525A1 (en) | 1998-07-23 | 2003-09-04 | Hoffmann James Arthur | FSH Formulation |
WO2000062795A2 (en) * | 1999-04-21 | 2000-10-26 | The Government Of The United States Of America, Represented By The Secretary, Department Of Healt H And Human Services The National Institutes Of Health | UTEROGLOBIN IN THE TREATMENT OF IgA MEDIATED AUTOIMMUNE DISORDERS |
US6413537B1 (en) | 2000-03-10 | 2002-07-02 | Wisconsin Alumni Research Foundation | Nystatin formulation having reduced toxicity |
US7256180B2 (en) | 2000-04-28 | 2007-08-14 | Supratek Pharma Inc. | Compositions and methods for inducing activation of dendritic cells |
MXPA04003640A (es) * | 2001-10-16 | 2005-04-11 | Rxkinetix Inc | Formulaciones de proteina de alta concentracion y metodo de fabricacion. |
EP1572719A4 (en) | 2002-02-20 | 2007-11-14 | Univ Minnesota | PARTIAL PEPTIDE MIMETICS AND METHOD |
EP1567191B1 (en) * | 2002-11-26 | 2010-09-08 | Eurocine Vaccines AB | Novel amine-based adjuvant |
CN100353997C (zh) * | 2003-02-28 | 2007-12-12 | 中外制药株式会社 | 稳定的含蛋白质的制剂 |
PT1610822E (pt) * | 2003-04-02 | 2011-01-05 | Ares Trading Sa | Formulações farmacêuticas líquidas ou liofilizadas de fsh e/ou lh em conjunto com o surfactante não iónico poloxâmero 188 e um agente bacteriostático |
US7838721B2 (en) * | 2003-04-09 | 2010-11-23 | Paragon Trade Brands, Llc | Disposable articles using high column AUL superabsorbents |
JP4871124B2 (ja) * | 2003-06-20 | 2012-02-08 | アレス トレーディング ソシエテ アノニム | 凍結乾燥fsh/lh製剤 |
US8377459B2 (en) * | 2003-07-09 | 2013-02-19 | The Procter & Gamble Company | Composition for wet wipes that enhances the efficacy of cleansing while being gentle to the skin |
WO2005034999A2 (en) * | 2003-10-10 | 2005-04-21 | Bvm Holding Co. | Composition comprising association complex of a pharmaceutical and a poloxamer |
US7150995B2 (en) * | 2004-01-16 | 2006-12-19 | Metrika, Inc. | Methods and systems for point of care bodily fluid analysis |
EP2813239B1 (en) * | 2004-08-04 | 2017-03-22 | Ipsen Biopharm Limited | Pharmaceutical composition containing botulinum neurotoxin A2 |
EP1778279B1 (en) * | 2004-08-04 | 2014-12-03 | Ipsen Biopharm Limited | Pharmaceutical composition containing botulinum neurotoxin a2 |
US20060173428A1 (en) * | 2005-02-02 | 2006-08-03 | Acors Deanna M | Absorbent article with logically correlated image and textual graphics |
CA2609038A1 (en) | 2005-05-18 | 2006-11-23 | Trinity Biosystems, Inc. | Methods and compositions for immunizing against chlamydia infection |
CU23432B6 (es) * | 2005-11-02 | 2009-10-16 | Ct Ingenieria Genetica Biotech | Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras |
US20110303542A1 (en) * | 2007-08-08 | 2011-12-15 | Advanced Liquid Logic, Inc. | Use of Additives for Enhancing Droplet Operations |
ES2669591T3 (es) | 2008-06-20 | 2018-05-28 | Novartis Ag | Inmunoglobulinas con agregación reducida |
PL2437785T3 (pl) | 2009-06-04 | 2015-08-31 | Novartis Ag | Sposoby identyfikacji miejsc sprzęgania IgG |
PE20130648A1 (es) | 2010-06-25 | 2013-07-03 | Shire Human Genetic Therapies | Tratamiento del sindrome de sanfilippo tipo b |
US9090691B2 (en) | 2010-09-15 | 2015-07-28 | Applied Molecular Transport Llc | Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences |
US11246915B2 (en) | 2010-09-15 | 2022-02-15 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
GB201116271D0 (en) * | 2011-09-21 | 2011-11-02 | Univ Cardiff | Dispersion anaesthetic device |
KR102598038B1 (ko) | 2014-05-07 | 2023-11-07 | 어플라이드 몰레큘라 트랜스포트 인크. | 생물학적 활성 화물의 경구 전달용 콜릭스 독소-유래 융합 분자 |
EP4082558B1 (en) | 2018-03-08 | 2023-08-23 | Applied Molecular Transport Inc. | Toxin-derived delivery constructs for oral delivery |
PT3762009T (pt) | 2018-03-08 | 2022-08-22 | Applied Molecular Transport Inc | Construções de administração derivadas de toxinas para administração oral |
AU2020331939A1 (en) | 2019-08-16 | 2022-03-24 | Applied Molecular Transport Inc. | Compositions, formulations, and interleukin production and purification |
CN115666522A (zh) * | 2020-03-18 | 2023-01-31 | Gi医诺微新 | 包含il-2蛋白和cd80蛋白的融合蛋白制剂 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3839314A (en) * | 1971-06-29 | 1974-10-01 | Baxter Laboratories Inc | Clarification of blood serum and plasma using block copolymers of ethylene oxide and polyoxypropylene |
US4478829A (en) * | 1983-04-28 | 1984-10-23 | Armour Pharmaceutical Company | Pharmaceutical preparation containing purified fibronectin |
US4933179A (en) * | 1983-08-22 | 1990-06-12 | Syntex (U.S.A.) Inc. | Feline leukemia virus antigen vaccines |
DE3406497A1 (de) * | 1984-02-23 | 1985-09-05 | Mueller Bernhard Willi Werner | Hochdisperse pharmazeutische mehrkomponentensysteme und verfahren zu ihrer herstellung |
US5234683A (en) * | 1985-06-18 | 1993-08-10 | Emory University | Method of stimulating the immune system |
US5039520A (en) * | 1986-05-15 | 1991-08-13 | Emory University | Plasma extender |
US5030448A (en) * | 1986-05-15 | 1991-07-09 | Emory University | Method of delivering drugs to damaged or diseased tissue |
US5041288A (en) * | 1986-05-15 | 1991-08-20 | Emory University | Method of treating tissue damaged by reperfusion injury |
US5152979A (en) * | 1986-05-15 | 1992-10-06 | Emory University | Method for treating vascular obstructions caused by abnormal cells |
US5182106A (en) * | 1986-05-15 | 1993-01-26 | Emory University | Method for treating hypothermia |
US5071649A (en) * | 1986-05-15 | 1991-12-10 | Emory University | Method of preventing blockage in catheters |
FR2608988B1 (fr) * | 1986-12-31 | 1991-01-11 | Centre Nat Rech Scient | Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules |
FR2634397B2 (fr) * | 1986-12-31 | 1991-04-19 | Centre Nat Rech Scient | Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules |
DE3875871T2 (de) * | 1987-02-20 | 1993-04-01 | Univ Emory | Antiinfektioese verbindungen und verfahren zur verwendung. |
WO1989001486A1 (en) * | 1987-08-11 | 1989-02-23 | New York University | Biologically active bactericidal/permeability-increasing protein fragments |
US5198541A (en) * | 1987-08-11 | 1993-03-30 | New York University | Dna encoding bactericidal/permeability-increasing proteins |
FR2630115B1 (fr) * | 1988-04-14 | 1994-10-28 | Merieux Inst | Procede de stabilisation des solutions d'albumine humaine et solution obtenue |
US5096885A (en) * | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
JPH02107163A (ja) * | 1988-10-15 | 1990-04-19 | Suntory Ltd | 新規なゲル状食品の製造方法 |
US5171739A (en) * | 1989-02-14 | 1992-12-15 | Incyte Pharmaceuticals, Inc. | Treatment of endotoxin-associated shock and preventation thereof using a BPI protein |
US5308834A (en) * | 1989-02-14 | 1994-05-03 | Incyte Pharmaceuticals, Inc. | Treatment of endotoxin-associated shock and prevention thereof using a BPI protein |
US5234912A (en) * | 1989-02-14 | 1993-08-10 | Incyte Pharmaceuticals, Inc. | Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof |
US5089274A (en) * | 1989-02-14 | 1992-02-18 | Incyte Pharmaceuticals, Inc. | Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders |
US5334584A (en) * | 1989-02-14 | 1994-08-02 | Incyte Pharamaceuticals, Inc. | Recombinant, non-glycosylated bpi protein and uses thereof |
US4997664A (en) * | 1989-09-05 | 1991-03-05 | Bryan Foods, Inc. | Method for packaging food products |
DE69128968T2 (de) * | 1990-12-03 | 1998-10-08 | Univ New York | Biologisch aktive bakterizide/permeabilitätserhöhende proteinbruchstücke |
ES2140408T3 (es) * | 1991-03-19 | 2000-03-01 | Cytrx Corp | Copolimeros de polioxipropileno/polioxietileno con actividad biologica mejorada. |
US5234908A (en) * | 1991-04-12 | 1993-08-10 | Creative Biomolecules, Inc. | Method of treating gastrointestinal ulcers with platelet derived growth factor |
JPH07502642A (ja) * | 1991-09-26 | 1995-03-23 | インサイト ファーマシューティカルズ,インコーポレイテッド | 新規な形態のリポ糖結合性タンパク質(lbp) |
US5643570A (en) * | 1992-05-19 | 1997-07-01 | Xoma Corporation | BPI-immunoglobulin fusion proteins |
ES2132239T3 (es) * | 1992-05-19 | 1999-08-16 | Xoma Corp | Metodos mejorados para la preparacion de proteinas de union a endotoxinas. |
AU695125B2 (en) * | 1993-02-02 | 1998-08-06 | Xoma Corporation | Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant |
US5348942A (en) * | 1993-03-12 | 1994-09-20 | Xoma Corporation | Therapeutic uses of bactericidal/permeability increasing protein products |
-
1994
- 1994-02-02 AU AU61330/94A patent/AU695125B2/en not_active Ceased
- 1994-02-02 CN CNB941913554A patent/CN1163264C/zh not_active Expired - Fee Related
- 1994-02-02 EP EP94907963A patent/EP0682524B1/en not_active Expired - Lifetime
- 1994-02-02 WO PCT/US1994/001239 patent/WO1994017819A1/en active IP Right Grant
- 1994-02-02 ES ES94907963T patent/ES2164098T3/es not_active Expired - Lifetime
- 1994-02-02 DK DK94907963T patent/DK0682524T3/da active
- 1994-02-02 AT AT94907963T patent/ATE206308T1/de not_active IP Right Cessation
- 1994-02-02 US US08/190,869 patent/US5488034A/en not_active Expired - Lifetime
- 1994-02-02 CA CA002155005A patent/CA2155005C/en not_active Expired - Fee Related
- 1994-02-02 DE DE69428521T patent/DE69428521T2/de not_active Expired - Fee Related
- 1994-02-02 JP JP51821394A patent/JP3946246B2/ja not_active Expired - Fee Related
- 1994-02-02 PT PT94907963T patent/PT682524E/pt unknown
-
1995
- 1995-06-07 US US08/472,995 patent/US5696090A/en not_active Expired - Fee Related
-
1997
- 1997-12-08 US US08/986,413 patent/US5955427A/en not_active Expired - Fee Related
-
1998
- 1998-12-24 HK HK98115456A patent/HK1014156A1/xx not_active IP Right Cessation
-
1999
- 1999-05-17 US US09/313,525 patent/US6066620A/en not_active Expired - Lifetime
-
2000
- 2000-02-11 US US09/502,356 patent/US6255284B1/en not_active Expired - Fee Related
-
2005
- 2005-02-25 JP JP2005052149A patent/JP2005145986A/ja not_active Withdrawn
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006502116A (ja) * | 2002-07-12 | 2006-01-19 | メダレックス, インク. | タンパク質の酸化分解を防ぐ方法及び組成物 |
WO2009034958A1 (ja) * | 2007-09-12 | 2009-03-19 | Jsr Corporation | タンパク安定化剤およびその製造方法、タンパク安定化剤の使用方法、ならびにタンパク安定化方法 |
JP5387850B2 (ja) * | 2007-09-12 | 2014-01-15 | Jsr株式会社 | タンパク安定化剤およびその製造方法、タンパク安定化剤の使用方法、ならびにタンパク安定化方法 |
WO2022202947A1 (ja) * | 2021-03-24 | 2022-09-29 | Jcrファーマ株式会社 | 安定な水性医薬組成物又は凍結乾燥医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
ES2164098T3 (es) | 2002-02-16 |
CA2155005C (en) | 1999-04-06 |
AU695125B2 (en) | 1998-08-06 |
EP0682524B1 (en) | 2001-10-04 |
US6066620A (en) | 2000-05-23 |
ATE206308T1 (de) | 2001-10-15 |
CN1163264C (zh) | 2004-08-25 |
US5955427A (en) | 1999-09-21 |
WO1994017819A1 (en) | 1994-08-18 |
DE69428521T2 (de) | 2002-05-23 |
US5488034A (en) | 1996-01-30 |
DK0682524T3 (da) | 2002-01-28 |
DE69428521D1 (de) | 2001-11-08 |
CA2155005A1 (en) | 1994-08-18 |
CN1127992A (zh) | 1996-07-31 |
JP3946246B2 (ja) | 2007-07-18 |
JP2005145986A (ja) | 2005-06-09 |
PT682524E (pt) | 2002-03-28 |
US5696090A (en) | 1997-12-09 |
EP0682524A1 (en) | 1995-11-22 |
US6255284B1 (en) | 2001-07-03 |
HK1014156A1 (en) | 1999-09-24 |
AU6133094A (en) | 1994-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH10513433A (ja) | 殺菌性、浸透性が向上したタンパク質及び界面活性剤を含有する医薬組成物 | |
EP2806886B1 (en) | Stabilised protein compositions based on semifluorinated alkanes | |
EP3000474B1 (en) | Nanoemulsion eyedrop composition containing cyclosporine and method for preparing same | |
JP7208302B2 (ja) | 抗ヒトtslp受容体抗体含有医薬組成物 | |
US6268345B1 (en) | Bactericidal/permeability-increasing protein (BPI) compositions | |
US20210179690A1 (en) | Ctla4-ig fusion protein formulation | |
WO2021231319A1 (en) | Il-2 fusion polypeptide compositions and methods of making and using the same | |
IL303607A (en) | A pharmaceutical preparation that includes FRATAXIN FUSION protein and methods of using it |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040511 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20040927 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20041102 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050225 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20050317 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20050922 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070411 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |